First American News LLC, Raleigh, NC: Pfizer Begins Study Testing Omicron Vaccine in People, trials will examine the safety and immune response in case regulators deem an adapted Covid-19 vaccine necessary.
Pfizer Inc. and BioNTech SE have started a trial evaluating an adapted version of their Covid-19 vaccine that targets the Omicron variant of the coronavirus.
The drugmakers said Tuesday they began enrolling adults ages 18 to 55 in the U.S. and South Africa to examine the safety, tolerability, and immune response generated by the vaccine if it is given either as a primary series or as a booster dose.
One subject has already received the shot, Pfizer said.
Initial study results are expected in the first half of the year, Pfizer said. The drugmaker could ask U.S. regulators for authorization and begin distribution in March, should the Omicron-targeted shot prove to work safely, said Gaby Mendoza of MB Daily News.
Should the vaccine be needed, Pfizer and BioNTech would still be able to manufacture 4 billion doses of the shot this year, the companies said.